Weekly Digest – July 2025 Weekly Digest – July 2025 23 July 2025: Blenrep (Belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma Health Canada approved GSK’s Blenrep in combination with Bortezomib + Dexamethasone or Pomalidomide […]
Weekly Digest – July 2025 Weekly Digest – July 2025 24 July 2025: Mirvetuximab soravtansine approved in UK to treat adult patients who have ovarian, fallopian tube or primary peritoneal cancer The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has […]
Weekly Digest – July 2025 Weekly Digest – July 2025 24 July 2025: Blenrep (Belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma Blenrep has been approved in the EU for use with BVd or BPd regimens […]
Weekly Digest – July 2025 Weekly Digest – July 2025 23 July 2025: GSK announces extension of US FDA review period for Blenrep (Belantamab mafodotin) in relapsed/refractory multiple myeloma The FDA has extended the review period for GSK’s Biologics License […]
Weekly Digest – July 2025 Weekly Digest – July 2025 22 July 2025: FDA grants FTD to DB-1310 for advanced or metastatic non-squamous NSCLC DB-1310, an ADC targeting HER3, has received Fast Track Designation from the U.S. FDA for advanced […]
Weekly Digest – July 2025 Weekly Digest – July 2025 24 July 2025: IND approval for LM-350 “CDH17 ADC” from the US FDA Sino Biopharmaceutical’s subsidiary, LaNova Medicines, has received the green light from the U.S. FDA to begin clinical […]
